Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED BALANCE SHEETS

December 31, December 31,

2007 2006

ASSETS (Note 1)

Current assets:

Cash and cash equivalents $11,726,126 $6,075,449

Marketable securities 35,957,933 57,029,199

Prepaids and other current

assets 945,583 1,082,817

Total current assets 48,629,642 64,187,465

Property and equipment, net 4,238,498 4,728,929

Deposits and other assets 377,798 359,974

Total assets $53,245,938 $69,276,368

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and other

accrued liabilities $4,515,426 $3,439,422

Accrued compensation 2,225,868 2,323,742

Current portion of deferred

revenue 1,227,031 2,260,478

Current portion of equipment

financing 953,940 885,273

Total current liabilities 8,922,265 8,908,915

Non-current portion of deferred

revenue - 1,143,159

Non
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... Communications, a leading provider of strategic communications services to corporations and ... the United States and Europe ... JD, is returning to the firm,s Washington, D.C. ... more than two years of service as Associate Commissioner for the ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. ... together with two institutes from the National Institutes of ... for bringing safer, more effective treatments to patients on ... Center for Advancing Translational Sciences (NCATS) and the National ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... United States in ... More Than a Decade, ... in diagnostic imaging, announced today that the U.S. Food,and Drug Administration ... intravenous use in,T1-weighted magnetic resonance imaging (MRI) of the liver to ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
... CFO-level financial and management services for technology and biotechnology companies, today ... office. Strickland is the latest partner to join the company's Boston ... ... Cambridge, MA (PRWEB) July 8, 2008 -- TechCFO, a leading ...
Cached Biology Technology:FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 2FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 3FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 4FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 5FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 6FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions 7MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8TechCFO Adds Gary Strickland as Partner in Boston Office 2
(Date:4/16/2014)... the world? Surprisingly, bacteria also face this problem. Theoretical ... how these organisms should decide how best to preserve ... is quite adaptable. It moves about in liquids and ... can stick to an underlying substrate. Actually, the bacteria ...
(Date:4/15/2014)... April 15, 2014, Irvine, Calif. UC Irvine neurobiologists have ... when transplanted into the brains of mice with the symptoms ... in the journal Stem Cells Research and Therapy , ... different mouse models. , Alzheimer,s disease, one of the ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from the ... to selective serotonin reuptake inhibitors (SSRIs), a frequently prescribed ... with autism spectrum disorder (ASD) and developmental delays (DD) ... of Pediatrics , analyzed data from large samples ...
Breaking Biology News(10 mins):Theoretical biophysics: Adventurous bacteria 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2
... be best known for their supersized canines, but they also ... fatal bite, says a new study in the journal ... extinct cat Smilodon fatalis roamed North and South ... as bison, camels, mastodons and mammoths. Telltale clues from bones ...
... While pregnant women may worry about the effects of air ... exposure to carbon monoxide and fine particles in the air ... preterm delivery or preeclampsia -- a serious condition that arises ... headed by a University at Buffalo epidemiologist. , The ...
... cell decide its particular identity? According to biologists at ... of T cellsimmune system cells that help destroy invading ... particular gene called Bcl11b. The activation of Bcl11b ... have decided to go on the T-cell pathway," says ...
Cached Biology News:Why you should never arm wrestle a saber-toothed tiger 2Air pollution doesn't increase risk of preeclampsia, early delivery, study finds 2Caltech biologists discover how T cells make a commitment 2Caltech biologists discover how T cells make a commitment 3
BAFF-R (CT) BR3 Affinity Purified Polyclonal Antibody...
HOXC11 Antibody...
HOXC11 Antibody...
PMM2 Immunogen: PMM2 (NP_000294, 47 a.a. ~ 112 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: